Uniting the Group’s strengths to realize our long-term vision, "Vision 110"
Under our corporate philosophy, "Kyorin shall fulfill its social mission of contributing to better health by cherishing life," our Group aims to enhance corporate value by developing healthcare businesses that truly contribute to people's health, centered on our ethical pharmaceutical business.
In April 2023, Kyorin Pharmaceutical Holdings, Inc. merged with its core subsidiary, KYORIN Pharmaceutical Co., Ltd., and changed its trade name to "KYORIN Pharmaceutical Co., Ltd." Furthermore, the Kyorin Group launched its long-term vision, "Vision 110," in fiscal 2023.
"Vision 110" is designed to embody our corporate philosophy. Our goal is to become "a company that contributes broadly to people's health by positioning the innovative drug business—which continuously provides high-value new drugs that meet medical needs—as its core, while simultaneously developing a diverse range of health-related businesses." We are dedicated to making this vision a reality.
The long-term vision, "Vision 110," is divided into three stages leading up to its final year (Stage 1: FY2023–2025; Stage 2: FY2026–2029; and Stage 3: FY2030–2032).With the conclusion of the first phase, our medium-term business plan "Vision 110 —Stage 1—," in fiscal 2025, we have launched the new medium-term business plan, "Vision 110 —Stage 2—," starting in fiscal 2026. Under the statement "Aggressive investment for sustainable growth," we will proactively advance five key business strategies. Our goal is to achieve our performance targets and further enhance the support and recognition we receive from all our stakeholders.
We sincerely ask our stakeholders for your continued understanding and support of the Kyorin Group.
Your Health is Kyorin’s Mission.
Representative Director, President and Chief Executive Officer
Yutaka Ogihara
